ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Sunday, October 26, 2025

10:30AM-12:30PM: Abstract Number: 0038

DNA Methylation Signatures of Smoking in Labial Salivary Gland Tissue in a Sjögren’s Disease Cohort

(0019–0048) Genetics, Genomics & Proteomics Poster

10:30AM-12:30PM: Abstract Number: 0379

Do Rheumatoid Arthritis Patients have Residual Fatigue Without Swollen Joints and Laboratory Inflammation? A Multicenter Study

(0357–0386) Patient Outcomes, Preferences, & Attitudes Poster I

10:30AM-12:30PM: Abstract Number: 0021

DoCTIS: A Single Cell RNA-Seq Atlas of Drug Response To Targeted Therapies

(0019–0048) Genetics, Genomics & Proteomics Poster

10:30AM-12:30PM: Abstract Number: 0336

Does Baseline Physical Function Moderate Change in Steps/day Following a Telephone-Delivered Walk With Ease Program?

(0306–0336) Osteoarthritis – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0462

Does Biological Sex Affect Mortality in Frail Patients with Rheumatoid Arthritis?

(0430–0469) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0748

Does The Number Of Arteries Affected At The Disease Onset Predict Relapses Of Giant Cell Arteritis?

(0731–0764) Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

10:30AM-12:30PM: Abstract Number: 0475

Drug Discontinuation in Inflammatory Arthritis Following Mandatory Non-Medical Switching from Originator to Biosimilar in Quebec, Canada

(0470–0505) Rheumatoid Arthritis – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0362

Drug Persistence of IL-17A Inhibitors Among Patients with PsA: Real-World Data from the CorEvitas PsA/SpA Registry

(0357–0386) Patient Outcomes, Preferences, & Attitudes Poster I

10:30AM-12:30PM: Abstract Number: 0497

Drug Survival and Discontinuation Reasons of Eight Biological Disease-Modifying Antirheumatic Drugs in 1,182 Patients with Rheumatoid Arthritis: A Retrospective Study Using the Niigata Orthopedic Rheumatoid Arthritis Database (NOSRAD)

(0470–0505) Rheumatoid Arthritis – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0568

Drug-Free Remission in Early Peripheral Spondyloarthritis: 10-year follow-up from the CRESPA-trial

(0554–0592) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0512

Dry Eye Disease Severity and Salivary Gland Biopsy in Patients with Primary Sjögren’s Syndrome

(0506–0521) Sjögren’s Disease – Basic & Clinical Science Poster I: Etiology, Pathogenesis, Diagnosis

10:30AM-12:30PM: Abstract Number: 0144

Duration of Anticoagulation in Antiphospholipid Antibody-positive Patients: Results from an AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Survey

(0115–0144) Antiphospholipid Syndrome Poster

10:30AM-12:30PM: Abstract Number: 0115

Dysfunctional Mitophagy Propels Neutrophil Hyperactivity and Thrombosis in Antiphospholipid Syndrome

(0115–0144) Antiphospholipid Syndrome Poster

10:30AM-12:30PM: Abstract Number: 0488

Early and Sustained Improvements in Disease Activity and Patient-Reported Outcomes in Patients Treated with Filgotinib for Rheumatoid Arthritis: Up to 2-Year Interim Real-World Data From FILOSOPHY and PARROTFISH

(0470–0505) Rheumatoid Arthritis – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0558

Early Systemic and Skin Pharmacodynamic Effects of Icotrokinra in Participants with Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3, ICONIC-LEAD Study

(0554–0592) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].